What are the clinical features, diagnosis, treatment, and prognosis of neurothekeoma?

Neurothekeoma: Clinical Features, Diagnosis, Treatment, and Prognosis

Overview

Neurothekeoma is a benign cutaneous neoplasm that predominantly affects young women (mean age 25-30 years) and most commonly presents as a solitary, nondescript papule or nodule on the head/neck or upper extremities. 1, 2

Clinical Features

Demographics and Location

• Female predominance of approximately 2:1, with 84% of patients under age 40 years 2
• Most common sites are upper extremities (35%) and head/neck (33%), followed by trunk, lower extremities, and rarely mucosa 1, 3, 2
• Mean tumor size is 1.1 cm, with 90% measuring less than 2 cm 2
• Age range spans from 15 months to 84 years, though pediatric cases are uncommon 3

Clinical Presentation

• Presents as a solitary, nondescript papule or nodule that is clinically nonspecific 1, 4
• No characteristic clinical features distinguish neurothekeoma from other dermal lesions, making histopathologic diagnosis essential 1

Diagnosis

Histopathologic Features

The diagnosis requires tissue biopsy showing characteristic nested or lobulated growth pattern with variable myxoid background, composed of epithelioid to spindle cells with eosinophilic or pale cytoplasm 1, 4, 2

Key Microscopic Features:

• Poorly marginated dermal proliferation with lobulated or micronodular architecture in most cases 2
• Nests and bundles of epithelioid to spindled cells separated by dense hyaline collagen 2
• Myxoid stroma present in 29% of cases; 8% are predominantly myxoid 2
• Low-grade cytologic atypia and mitotic activity are common (mean 3 mitoses per 10 HPF) 4, 2
• Osteoclastic giant cells observed in 15% of cases 2

Tissue Involvement:

• 52% limited to dermis; 48% involve superficial subcutaneous tissue 2
• 25% infiltrate fat; 8% entrap skeletal muscle (predominantly facial lesions) 2

Immunohistochemistry

All neurothekeomas are uniformly negative for S-100 protein, which is the single most important distinguishing feature from melanocytic lesions 4, 2

• Positive for NKI-C3 in 100% of cases 2
• Neuron-specific enolase positive in 89% 2
• Smooth muscle actin focally positive in 57% 2
• Desmin, myelin basic protein, and epithelial membrane antigen are negative 4

Differential Diagnosis

The most critical differential diagnoses include spindle and epithelioid cell (Spitz) nevus, malignant melanoma (particularly desmoplastic-neurotropic melanoma), cellular blue nevus, and fibrohistiocytic proliferations 4

Common misdiagnoses include leiomyosarcoma, malignant nodular hidradenoma, and clear cell hidradenoma, emphasizing the need for expert pathologic review 1

Atypical Features That Do NOT Indicate Malignancy

Despite concerning histologic features, neurothekeomas remain benign with no documented metastatic potential 5, 2

Features That May Cause Diagnostic Concern:

• Large size up to 6 cm 5
• Deep penetration into skeletal muscle or subcutaneous fat 5
• Diffusely infiltrative borders 5
• High mitotic rate (21% have ≥5 mitoses per 10 HPF) 2
• Marked cytologic pleomorphism (present in 25% of cases) 5, 2
• Vascular invasion 5

None of these atypical features correlate with recurrence or adverse outcome 2

Treatment

Complete surgical excision with frozen section control of margins is the recommended treatment 1

Surgical Approach:

• Wide local excision is the standard approach for most lesions 1
• Mohs micrographic surgery is appropriate for cosmetically sensitive areas such as the nasal ala 1
• Ensure negative margins at time of excision to prevent recurrence 2

Critical Management Points:

• No role for radiation therapy, chemotherapy, or adjuvant treatment 1
• Avoid overly aggressive therapy based on atypical histologic features 4

Prognosis

Neurothekeoma is a benign neoplasm with excellent prognosis following complete excision 1, 2

Recurrence:

• Local recurrence occurs in approximately 7.5% of cases (10 of 133 in the largest series) 2
• All documented recurrences occurred after marginal excision or involved excision margins 2
• Mean time to recurrence is 18 months 2
• Seven of 10 recurrences were situated on the face 2
• Re-excision with clear margins is curative for recurrent lesions 1

Long-term Outcome:

• Follow-up data ranging from 5 to 146 months (mean 44 months) show no metastases or malignant transformation 2
• Preliminary follow-up of 1-5 years for atypical cases shows no recurrence when completely excised 5
• All patients treated with wide local excision were without evidence of disease at median 8 months follow-up (range 0-35 months) 1

Critical Clinical Pitfalls

• Neurothekeoma is commonly misdiagnosed both pathologically and clinically; maintain high index of suspicion for spindle cell dermal lesions in young women 1
• Do not pursue aggressive oncologic treatment based on atypical histologic features, as these do not predict malignant behavior 4, 5
• Ensure adequate tissue sampling for immunohistochemistry; S-100 negativity is essential to exclude melanocytic lesions 4
• Facial lesions have higher recurrence rates; ensure complete excision with margin control 2
• Incomplete excision is the only factor associated with recurrence; re-excision should be performed if margins are positive 2